Humacyte, an Access Industries-backed developer of tissue-based biological repair technology, has now raised $290m in financing in total.

Humacyte, a US-headquartered developer of tissue-based medical technology that counts conglomerate Access Industries as an investor, completed a $75m series C round on Friday.

The round was led by a consortium including hedge fund sponsor PointState Capital and a range of undisclosed existing private investors and new investors.

Founded in 2004, Humacyte is working on regenerative medicine and vascular surgery technology and has products at the preclinical and clinical stage. It seeks to engineer its own extracellular tissues capable of…